Below is a structured extraction and summary of the **relevant and actionable financial information** from Suven Life Sciences Limited’s results filing dated November 11, 2025, for the quarter and half-year ended September 30, 2025. --- ## 1. Auditor’s Note - **Standalone and Consolidated Financial Results** for Q2 FY26 (quarter ended 30 Sep 2025) have been reviewed by statutory auditors (KARVY & CO). - **No qualifications, concerns, or issues** reported in the auditor’s review reports for both standalone and consolidated results. - Auditor’s conclusion: The financial statements are prepared in accordance with applicable Indian Accounting Standards (Ind AS) and do not contain any material misstatements. - The subsidiary’s interim financials (Suven Neurosciences, Inc.) were reviewed by another auditor; their reports were relied upon without modification to the conclusion. **Actionable:** No auditor qualifications; results can be considered reliable for analysis. --- ## 2. Financial Performance ### Periods Covered: - Latest quarter: Q2 FY26 (Jul-Sep 2025) - Immediately preceding quarter: Q1 FY26 (Apr-Jun 2025) - Same quarter previous year: Q2 FY25 (Jul-Sep 2024) - Half-year ended Sep 30, 2025 (H1 FY26) - Half-year ended Sep 30, 2024 (H1 FY25) - Full financial year ended Mar 31, 2025 (FY25) ### Key Financials (Rs. in Lakhs) | Metric | Q2 FY26 (Sep 2025) | Q1 FY26 (Jun 2025) | Q2 FY25 (Sep 2024) | H1 FY26 (Apr-Sep 2025) | H1 FY25 (Apr-Sep 2024) | FY25 (Apr 24-Mar 25) | |-----------------------------|--------------------|--------------------|--------------------|------------------------|------------------------|----------------------| | **Standalone** | | | | | | | | Revenue from operations | 91.92 | 186.67 | 257.29 | 278.59 | 357.89 | 665.58 | | Other Income | 377.78 | 58.90 | 403.48 | 436.68 | 796.58 | 1,072.59 | | **Total Income** | 469.70 | 245.57 | 660.77 | 715.27 | 1,154.47 | 1,738.17 | | Employee Benefits Expense | 607.65 | 597.56 | 520.34 | 1,205.21 | 989.30 | 2,082.49 | | Depreciation & Amortisation | 131.68 | 136.84 | 145.51 | 268.52 | 294.15 | 582.17 | | R&D Expenses | 877.32 | 518.77 | 908.96 | 1,396.09 | 1,367.94 | 3,043.16 | | Other Expenses | 397.56 | 470.27 | 191.59 | 867.83 | 372.99 | 733.67 | | **Total Expenses** | 2,014.21 | 1,723.44 | 1,767.96 | 3,737.65 | 3,028.25 | 6,446.15 | | Profit before Tax | (1,544.51) | (1,477.87) | (1,107.19) | (3,022.38) | (1,873.78) | (4,707.98) | | Net Profit/(Loss) | (1,544.51) | (1,477.87) | (1,107.19) | (3,022.38) | (1,873.78) | (4,707.98) | | EPS (Basic & Diluted) | (0.70) | (0.68) | (0.51) | (1.36) | (0.86) | (2.16) | | Metric | Q2 FY26 (Sep 2025) | Q1 FY26 (Jun 2025) | Q2 FY25 (Sep 2024) | H1 FY26 (Apr-Sep 2025) | H1 FY25 (Apr-Sep 2024) | FY25 (Apr 24-Mar 25) | |-----------------------------|--------------------|--------------------|--------------------|------------------------|------------------------|----------------------| | **Consolidated** | | | | | | | | Revenue from operations | 91.92 | 186.67 | 257.29 | 278.59 | 357.89 | 665.58 | | Other Income | 377.80 | 59.98 | 403.56 | 437.78 | 804.39 | 1,089.69 | | **Total Income** | 469.72 | 246.65 | 660.85 | 716.37 | 1,162.28 | 1,755.27 | | Employee Benefits Expense | 607.65 | 597.56 | 520.34 | 1,205.21 | 989.30 | 2,082.49 | | Depreciation & Amortisation | 131.68 | 136.84 | 145.51 | 268.52 | 294.15 | 582.17 | | R&D Expenses | 7,032.13 | 4,148.84 | 4,758.49 | 11,180.97 | 7,250.36 | 14,396.18 | | Other Expenses | 429.25 | 515.10 | 199.33 | 944.35 | 392.95 | 764.27 | | **Total Expenses** | 8,200.71 | 5,398.34 | 5,625.23 | 13,599.05 | 8,930.63 | 17,829.77 | | Profit before Tax | (7,730.99) | (5,151.69) | (4,964.38) | (12,882.68) | (7,768.35) | (16,074.50) | | Net Profit/(Loss) | (7,730.99) | (5,151.69) | (4,964.38) | (12,882.68) | (7,768.35) | (16,074.50) | | EPS (Basic & Diluted) | (3.48) | (2.36) | (2.27) | (5.80) | (3.56) | (7.37) | --- ### Margins and Observations: - **Standalone**: Operating loss continues with net loss increasing QoQ and YoY. - Revenue from operations declined sharply QoQ (Q2 FY26 Rs. 91.92L vs Q1 FY26 Rs. 186.67L) and YoY (Q2 FY25 Rs. 257.29L). - Other income is a significant contributor (~4x revenue from operations), mainly from investments. - R&D expenses remain high and increased QoQ in standalone (Rs. 877.32L vs Rs. 518.77L). - Consolidated results show much larger losses driven by the subsidiary Suven Neurosciences, Inc. (net loss for Q2 FY26 Rs. 7,730.99L). - EPS remains negative across all periods. --- ## 3. Detailed Notes / Management Commentary - **Business Focus:** Drug discovery and development of New Chemical Entities (NCEs) in CNS disorders. - **Subsidiary:** Suven Neurosciences, Inc. (wholly owned) involved in clinical development; its losses significantly impact consolidated results. - **Clinical Pipeline:** - SUVN-502 (Masupirdine): Ongoing Phase 3 study in US/Europe; expected completion by end 2026. - SUVN-G3031 (Samelisant): Phase 3 planned by end FY26. - SUVN-911 (Ropanicant): Phase 2B ongoing; completion expected end 2026. - SUVN-D4010 (Usmarapride): Phase 2 planned in 2026. - SUVN-I6107: Phase 1 ongoing; expected completion FY26. - **Patents:** 17 patents granted during the period across multiple countries. - **ESOP:** Employee benefit expense of Rs. 26.35 lakhs recognized in Q2 FY26; 2,14,000 options exercised raising Rs. 117.70 lakhs. - **Preferential Issue:** - 6.4 crore convertible warrants approved; 9.18 million shares allotted during the quarter on conversion. - Total proceeds received Rs. 30,673.43 lakhs; Rs. 5,424.12 lakhs utilized; balance Rs. 25,249.31 lakhs as of Sep 30, 2025. - **Accounting Policies:** Prepared as per Ind AS; no changes or material adjustments reported. - **No segment reporting** as company operates in a single business segment (R&D). --- ## 4. Segment Information - **Single business segment:** Research & Development. - No segment-wise financials provided. - No geographic or product-wise breakdown. - Segment reporting not applicable as per Ind AS 108. --- ## 5. Capex, Projects, and Corporate Activity - **Capital Expenditure:** Rs. 213.74 lakhs spent in H1 FY26 (Standalone and Consolidated). - **Ongoing Projects:** Clinical trials as per pipeline above. - **No impairments, write-downs, or exceptional items** reported. - **Corporate Activity:** - Preferential issue of convertible warrants and subsequent allotment of shares. - ESOP exercises raising equity capital. - **Cash Flow Highlights:** - Standalone: Net cash used in operating activities Rs. (3,339.75) lakhs; investing activities Rs. (26,551.89) lakhs; financing activities Rs. 29,954.28 lakhs. - Consolidated: Net cash used in operating activities Rs. (10,338.01) lakhs; investing activities Rs. (20,157.90) lakhs; financing activities Rs. 29,954.28 lakhs. - **Significant increase in investments in mutual funds and other financial assets** (reflected in balance sheet and cash flows). --- ## 6. Standalone vs Consolidated | Aspect | Standalone | Consolidated | |-----------------------------|-----------------------------------|-----------------------------------| | Revenue from operations | Rs. 91.92L (Q2 FY26) | Rs. 91.92L (Q2 FY26) | | Other Income | Rs. 377.78L (Q2 FY26) | Rs. 377.80L (Q2 FY26) | | Total Income | Rs. 469.70L (Q2 FY26) | Rs. 469.72L (Q2 FY26) | | Net Loss (Q2 FY26) | Rs. (1,544.51)L | Rs. (7,730.99)L | | EPS (Basic & Diluted) | (0.70) per share | (3.48) per share | | Total Assets (Sep 30, 2025) | Rs. 108,102.64L | Rs. 33,741.00L | | Equity (Sep 30, 2025) | Rs. 106,933.73L | Rs. 28,127.41L | - Consolidated losses are significantly higher due to the subsidiary’s clinical development expenses. - Standalone financials show smaller losses and stable asset base dominated by investments. - Cash and cash equivalents higher in consolidated (Rs. 960.93L) vs standalone (Rs. 108.99L) due to subsidiary cash balances. --- ## Summary for Investment Analysis Team | Topic | Key Points | |-----------------------------|------------------------------------------------------------------------------------------------| | **Auditor’s Note** | Clean review reports with no qualifications or issues. | | **Financial Performance** | - Continued losses at standalone and consolidated levels; consolidated losses much larger.
- Revenue from operations declined QoQ and YoY.
- Other income (mainly investment income) is a significant income source.
- R&D expenses remain high and increasing.
- EPS negative across all periods.
- Cash flow negative from operations; financing via equity raises supports cash needs. | | **Management Commentary** | - Focus on CNS drug development with multiple clinical trials ongoing/planned.
- 17 patents granted.
- ESOP exercised and preferential equity issue raised significant funds.
- No changes in accounting policies or material adjustments.
- Single business segment (R&D). | | **Segment Information** | Not applicable; single segment only. | | **Capex & Corporate Activity** | - Capex Rs. 213.74 lakhs in H1 FY26.
- Preferential issue proceeds Rs. 30,673.43 lakhs; Rs. 5,424.12 lakhs utilized.
- No impairments or restructuring.
- Significant investment in mutual funds and financial assets.
- Equity infusion supports cash burn from clinical development. | | **Standalone vs Consolidated** | - Consolidated losses driven by subsidiary Suven Neurosciences, Inc.
- Standalone financials show smaller losses and strong investment asset base.
- Consolidated cash balances higher due to subsidiary. | --- **No immediate red flags or auditor concerns. The company is in a heavy investment phase with ongoing clinical trials and R&D, funded by equity raises and investment income. Losses are expected given the clinical development stage. Monitor cash utilization and progress of clinical programs closely.** --- **End of Analysis**